(Hypertension. 1997;30:1318-1324.)
© 1997 American Heart Association, Inc.
Articles |
A Mouse View of Hypertension
From the Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill.
Correspondence to Oliver Smithies, D. Phil, Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, CB #7525, 701 Brinkhous Bullitt Building, Chapel Hill, NC 27599-7525.
Abstract Essential hypertension probably results from combinations of genetic variations, not necessarily the same in all afflicted persons, which individually may not cause sufficient deviation from normality to be significantly harmful.
Genes contributing to hypertension are being sought by analytic experiments aimed at identifying candidate genes associated or segregating with the phenotype in humans and animals and by synthetic experiments in which changes are made in candidate genes in animals and their effects on blood pressure are determined.
We have used gene targeting to vary the amounts of angiotensinogen and angiotensin-converting enzyme (ACE) synthesized from their genes (Agt and Ace). These "gene titration" experiments establish that changes in Agt gene expression cause changes in the blood pressures of mice. Surprisingly, quantitative changes in Ace gene expression over a threefold range do not affect blood pressures.
Computer simulations with a simple version of the renin-angiotensin system predict that changes in Agt function alter the steady state levels of both angiotensin I (Ang I) and angiotensin II (Ang II). In contrast, modest changes in Ace function alter Ang I levels considerably but scarcely affect Ang II levels. Simulations over the ranges of ACE levels that can be achieved with ACE inhibitors predict that Ang II levels will decrease only when Ang I levels have plateaued.
Comparisons of the computer simulations with our genetic experiments and with prior work of others using wide dose ranges of ACE inhibitor show a satisfactory agreement and help reconcile the apparent contradictions between the genetic and pharmacological experiments.
Key Words: hypertension, essential • renin-angiotensin system • gene targeting • genetic variations
This article has been cited by other articles:
 |
|
 |
|
  H. Kobori, A. B. Alper Jr, R. Shenava, A. Katsurada, T. Saito, N. Ohashi, M. Urushihara, K. Miyata, R. Satou, L. L. Hamm, et al. Urinary Angiotensinogen as a Novel Biomarker of the Intrarenal Renin-Angiotensin System Status in Hypertensive Patients Hypertension, February 1, 2009; 53(2): 344 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kobori, M. Nangaku, L. G. Navar, and A. Nishiyama The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease Pharmacol. Rev., September 1, 2007; 59(3): 251 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-M. Lalouel and A. Rohrwasser Genetic Susceptibility to Essential Hypertension: Insight From Angiotensinogen Hypertension, March 1, 2007; 49(3): 597 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Muller and F. C. Luft Direct Renin Inhibition with Aliskiren in Hypertension and Target Organ Damage Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 221 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Reckelhoff Gender Differences in the Regulation of Blood Pressure Hypertension, May 1, 2001; 37(5): 1199 - 1208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobori, L. M. Harrison-Bernard, and L. G. Navar Enhancement of Angiotensinogen Expression in Angiotensin II-Dependent Hypertension Hypertension, May 1, 2001; 37(5): 1329 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J Arendshorst Review: Lessons on renal function from transgenic mice lacking different angiotensin II receptors Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S167 - S175. [PDF]
|
|
|
|
 |
|
 T. Rankinen, J. Gagnon, L. Perusse, Y. C. Chagnon, T. Rice, A. S. Leon, J. S. Skinner, J. H. Wilmore, D. C. Rao, and C. Bouchard AGT M235T and ACE ID polymorphisms and exercise blood pressure in the HERITAGE Family Study Am J Physiol Heart Circ Physiol, July 1, 2000; 279(1): H368 - H374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schmitz, M. Gotthardt, S. Hinderlich, J.-R. Leheste, V. Gross, H. Vorum, E. I. Christensen, F. C. Luft, S. Takahashi, and T. E. Willnow Normal Blood Pressure and Plasma Renin Activity in Mice Lacking the Renin-binding Protein, a Cellular Renin Inhibitor J. Biol. Chem., May 12, 2000; 275(20): 15357 - 15362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Rankinen, L. Perusse, J. Gagnon, Y. C. Chagnon, A. S. Leon, J. S. Skinner, J. H. Wilmore, D. C. Rao, and C. Bouchard Angiotensin-converting enzyme ID polymorphism and fitness phenotype in the HERITAGE Family Study J Appl Physiol, March 1, 2000; 88(3): 1029 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Rapp Genetic Analysis of Inherited Hypertension in the Rat Physiol Rev, January 1, 2000; 80(1): 135 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. PRADERVAND, Q. WANG, M. BURNIER, F. BEERMANN, J. D. HORISBERGER, E. HUMMLER, and B. C. ROSSIER A Mouse Model for Liddle's Syndrome J. Am. Soc. Nephrol., December 1, 1999; 10(12): 2527 - 2533. [Abstract] [Full Text]
|
|
|
|
|
|
J. Zicha and J. Kunes Ontogenetic Aspects of Hypertension Development: Analysis in the Rat Physiol Rev, October 1, 1999; 79(4): 1227 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. TAKAHASHI and O. SMITHIES Gene Targeting Approaches to Analyzing Hypertension J. Am. Soc. Nephrol., July 1, 1999; 10(7): 1598 - 1605. [Abstract] [Full Text]
|
|
|
|
|
|
M. I. Phillips Is Gene Therapy for Hypertension Possible? Hypertension, January 1, 1999; 33(1): 8 - 13. [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Coffman Gene targeting in physiological investigations: studies of the renin-angiotensin system Am J Physiol Renal Physiol, June 1, 1998; 274(6): F999 - F1005. [Abstract] [Full Text] [PDF]
|
|